Literature DB >> 23707665

Incidence and management of edema associated with trebananib (AMG 386).

Bradley J Monk1, Lindsey Minion, Sandrina Lambrechts, Ignace B Vergote, Nele Devoogdt, Beth Y Karlan.   

Abstract

Entities:  

Keywords:  AMG 386; Anti-angiogenic agent; Edema; Ovarian cancer; Trebananib

Mesh：

Substances：

Year:  2013        PMID： 23707665     DOI： 10.1016/j.ygyno.2013.05.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  5 in total

1.  Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors.

Authors:  Jennifer R Diamond; Benjamin Wu; Neeraj Agarwal; Daniel W Bowles; Elaine T Lam; Theresa L Werner; Erik Rasmussen; Erick Gamelin; Felipe Soto; Greg Friberg; Yu-Nien Sun; Sunil Sharma
Journal:  Invest New Drugs       Date:  2015-04-21       Impact factor: 3.850

Review 2.  Therapeutic targeting of the angiopoietin-TIE pathway.

Authors:  Pipsa Saharinen; Lauri Eklund; Kari Alitalo
Journal:  Nat Rev Drug Discov       Date:  2017-05-19       Impact factor: 84.694

Review 3.  New ways to successfully target tumor vasculature in ovarian cancer.

Authors:  Xiaoyun Yang; Fangrong Shen; Wei Hu; Robert L Coleman; Anil K Sood
Journal:  Curr Opin Obstet Gynecol       Date:  2015-02       Impact factor: 1.927

Review 4.  Anti-angiogenic agents in ovarian cancer: past, present, and future.

Authors:  B J Monk; L E Minion; R L Coleman
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

5.  Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials.

Authors:  Yanyan Jiang; Xiaomei Sun; Beihua Kong; Jie Jiang
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.